Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats.

Briyal S, Gulati K, Gulati A

Brain research19 Oct 2011Cited by 59 (Europe PMC)

PMID22055454DOI10.1016/j.brainres.2011.10.026PepBankPUB-22055454

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with cerebral ischemia, exendin‑4 reduced infarct volume by 27% versus vehicle.
In plain wordsIn rats with cerebral ischemia, exendin‑4 reduced infarct volume by 27% compared with vehicle.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInfarct volume
Study
ratn: not reported in source
Permanent middle cerebral artery occlusion
Comparator
Vehicle
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
0.5 μg/kg twice daily · intraperitoneal · 7 daysAs given in this study (rat).
Measurements
Infarct volume reduction
27%
exendin-4 versus vehicle
Source sentences
Summary
The infarct volume was 27% less compared to vehicle treated rats.
2 context sentences(design, population, supporting numbers)
Summary · context
We explored the effect of repeated administration of exendin-4 (0.5 μg/kg, intraperitoneal twice a day for 7 days)
Summary · context
following cerebral ischemia produced in rats by permanent middle cerebral artery occlusion (MCAO).
Report a problemFND-2205545401
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with cerebral ischemia, exendin‑4 reduced neurological deficit versus control.
In plain wordsIn rats with cerebral ischemia, exendin‑4 reduced neurological deficit compared with control.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNeurological deficit
Study
ratn: not reported in source
Permanent middle cerebral artery occlusion
Comparator
Vehicle
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
0.5 μg/kg twice daily · intraperitoneal · 7 daysAs given in this study (rat).
Source sentences
Summary
The neurological deficit following MCAO was lower and oxidative stress parameters were improved in exendin-4 treated rats compared to control.
2 context sentences(design, population, supporting numbers)
Summary · context
We explored the effect of repeated administration of exendin-4 (0.5 μg/kg, intraperitoneal twice a day for 7 days)
Summary · context
following cerebral ischemia produced in rats by permanent middle cerebral artery occlusion (MCAO).
Report a problemFND-2205545402
03AnimalAnimal study (in vivo)Mechanism
In rats with cerebral ischemia, exendin‑4 improved oxidative stress parameters versus control, without separate marker results.
In plain wordsIn rats with cerebral ischemia, exendin‑4 improved oxidative stress measures compared with control.
Peptide
Exenatide (exendin-4)
Outcome
MixedOxidative stress parameters
Study
ratn: not reported in source
Permanent middle cerebral artery occlusion
Comparator
Vehicle
Outcome group
Oxidative stress · Nervous system and cognition
Studied dose
0.5 μg/kg twice daily · intraperitoneal · 7 daysAs given in this study (rat).
Source sentences
Summary
The neurological deficit following MCAO was lower and oxidative stress parameters were improved in exendin-4 treated rats compared to control.
2 context sentences(design, population, supporting numbers)
Summary · context
We explored the effect of repeated administration of exendin-4 (0.5 μg/kg, intraperitoneal twice a day for 7 days)
Summary · context
following cerebral ischemia produced in rats by permanent middle cerebral artery occlusion (MCAO).
Report a problemFND-2205545403
04AnimalAnimal study (in vivo)Mechanism
In rats with cerebral ischemia, exendin‑4 did not affect the ischemia-associated increase in ET(A) receptor expression.
In plain wordsIn rats with cerebral ischemia, exendin‑4 did not change the increase in ET(A) receptor expression.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeET(A) receptor expression
Study
ratn: not reported in source
Permanent middle cerebral artery occlusion
Comparator
Vehicle
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
0.5 μg/kg twice daily · intraperitoneal · 7 daysAs given in this study (rat).
Source sentences
Summary
Expression of ET(A) receptors was significantly increased following cerebral ischemia which was not affected by exendin-4 treatment or by BQ123 administration.
2 context sentences(design, population, supporting numbers)
Summary · context
We explored the effect of repeated administration of exendin-4 (0.5 μg/kg, intraperitoneal twice a day for 7 days)
Summary · context
following cerebral ischemia produced in rats by permanent middle cerebral artery occlusion (MCAO).
Report a problemFND-2205545406
05AnimalAnimal study (in vivo)Mechanism
In rats with cerebral ischemia, exendin‑4 did not change ET(B) receptor expression.
In plain wordsIn rats with cerebral ischemia, exendin‑4 did not change ET(B) receptor expression.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeET(B) receptor expression
Study
ratn: not reported in source
Permanent middle cerebral artery occlusion
Comparator
Vehicle
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
0.5 μg/kg twice daily · intraperitoneal · 7 daysAs given in this study (rat).
Source sentences
Summary
No change in expression of ET(B) receptors was observed following cerebral ischemia or any treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We explored the effect of repeated administration of exendin-4 (0.5 μg/kg, intraperitoneal twice a day for 7 days)
Summary · context
following cerebral ischemia produced in rats by permanent middle cerebral artery occlusion (MCAO).
Report a problemFND-2205545407

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

06AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In ischemic rats, BQ123 improved infarct volume, oxidative stress parameters and neurological deficit in both exendin‑4 and vehicle groups.
In plain wordsIn rats with cerebral ischemia, BQ123 improved injury outcomes in both exendin‑4 and vehicle groups.
Peptide
Exenatide (exendin-4)
Outcome
MixedCombined ischemic injury outcomes with BQ123
Study
ratn: not reported in source
Permanent middle cerebral artery occlusion
Comparator
Without BQ123
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
BQ123 significantly improved infarct volume, oxidative stress parameters and neurological deficit in ischemic rats treated with vehicle or exendin-4.
2 context sentences(design, population, supporting numbers)
Summary · context
We explored the effect of repeated administration of exendin-4 (0.5 μg/kg, intraperitoneal twice a day for 7 days)
Summary · context
following cerebral ischemia produced in rats by permanent middle cerebral artery occlusion (MCAO).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2205545404
07AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Mechanism
In rats with cerebral ischemia, BQ123-induced protection was similar with exendin‑4 and vehicle treatment.
In plain wordsIn rats with cerebral ischemia, BQ123 protection was similar in exendin‑4 and vehicle groups.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBQ123-induced protection
Study
ratn: not reported in source
Permanent middle cerebral artery occlusion
Comparator
Vehicle-treated rats receiving BQ123
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
BQ123 induced protection from cerebral ischemia was similar in vehicle or exendin-4 treated rats.
2 context sentences(design, population, supporting numbers)
Summary · context
We explored the effect of repeated administration of exendin-4 (0.5 μg/kg, intraperitoneal twice a day for 7 days)
Summary · context
following cerebral ischemia produced in rats by permanent middle cerebral artery occlusion (MCAO).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2205545405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.